Navigation Links
GeoVax Labs, Inc. Moving Operations to Smyrna, Georgia
Date:10/20/2009

ent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person become infected. GeoVax AIDS vaccines also may be effective as a therapeutic treatment (for people already infected with the HIV-1 virus).

GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of Research and Development, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.

GeoVax's AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $17 million IPCAVD grant awarded in late 2007.

Safe Harbor Statement

All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its Fillanthropy(TM) Program
2. Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy
3. GeoVax Labs Requests pre-IND Meeting With FDA
4. GeoVax to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
5. GeoVax Labs, Inc. Provides Clinical Studies Update
6. GeoVax Labs, Inc. Announces Resignation of Director
7. GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois
8. GeoVax to Exhibit at the 2009 BIO International Convention
9. GeoVax Labs, Inc. Announces First Quarter Financial Results
10. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
11. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015  AsureQuality and Ubiquitome have ... for applications in food and primary production sectors. ... real-time PCR device, the Freedom4. AsureQuality ... to the supermarket shelf for producers, processors and ... in animal disease control and pest management and ...
(Date:7/29/2015)... ... July 29, 2015 , ... G-CON Manufacturing, Inc., the ... their 2nd generation cell therapy POD® design. The 2nd generation portfolio not only ... a new POD® design. , “G-CON first offered our miniPOD CT product ...
(Date:7/29/2015)... , July 29, 2015 ... has announced the addition of the "Global ... their offering. The Global Biosimilars Market, ... of the rapidly growing biosimilars market. With the ... striving to minimize costs, biosimilars are being viewed ...
(Date:7/29/2015)... ... July 29, 2015 , ... Brady (NYSE:BRC), a ... Label Guide . To align chemical container labeling with OSHA’s updated Hazard Communication ... label components, an example of an accurate label, and pictogram uses and meanings. ...
Breaking Biology Technology:AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Brady Announces a New GHS Label Guide 2
... clearance for two new brain imaging applications, a local ... products to healthcare providers. , ,Approval from the ... Radiologic Health in June allowed Kyron Clinical ... line of brain mapping solutions based on functional and ...
... , Wis. - Platypus Technologies recently ... new line of products and court strategic partners - ... and nanotechnology company is prepared to expand its product ... used by researchers, and management is in discussions with ...
... Wis. - Local angel investor network Silicon ... Clearent, LLC , which is developing a next-generation credit ... , ,It's not unusual for Wisconsin-based investors to look ... of Silicon Pastures, said this investment opportunity arrived at ...
Cached Biology Technology:Kyron wins FDA approval for brain imaging technology 2Platypus ready to unveil new commercial lines 2Platypus ready to unveil new commercial lines 3Platypus ready to unveil new commercial lines 4
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
(Date:7/23/2015)... July 23, 2015 Aware, Inc. (NASDAQ: AWRE ... reported financial results for its second quarter ended June 30, ... 2015 was $4.5 million, a decrease of 33% compared to ... in the second quarter of 2015 was $0.3 million, or ... $0.04 per diluted share, in the same period a year ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... BOZEMAN, Mont. -- Research by a Montana State ... paleontologists is upending more than 100 years of thought ... Since the late 1800s, scientists have believed that Triceratops ... had a three-horned skull with a rather short frill, ...
... Rice University scientists have found the "ultimate" solvent for ... brings the creation of a highly conductive quantum nanowire ... of bundling, making them less useful than when they,re ... Pasquali, a professor in chemical and biomolecular engineering and ...
... of care comprised of surgery, radiation and chemotherapy ... number of biological responses that may actually feed the energy ... writing in the journal Lancet Oncology . The ... of about a year from diagnosis. Just three percent of ...
Cached Biology News:Montana State researchers say Triceratops, Torsaurus were same dinosaur at different stages 2Montana State researchers say Triceratops, Torsaurus were same dinosaur at different stages 3Montana State researchers say Triceratops, Torsaurus were same dinosaur at different stages 4Nanotubes pass acid test 2Nanotubes pass acid test 3Does the existing standard of care supply energy sources to brain tumor cells? 2